862187-64-2

Upstream product

• 67-56-1 methanol 
• 51699-46-8 1-(3-bromophenyl)propane-1,3-diol 
• 3132-99-8 m-bromobenzoic aldehyde 
• 51699-41-3 ethyl 3-hydroxy-3-(3-bromophenyl)-propanoate 
• 201230-82-2 carbon monoxide 

Downstream Products

• 928780-45-4 3-{2-[5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-tetrahydro-furan-2-ylmethoxy]-2-oxo-2λ⁵-[1,3,2]dioxaphosphinan-4-yl}-benzoic acid methyl ester 

Relevant academic research and scientific papers

NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES

Novel 2'-C-methyl nucleoside 5 '-monophosphate and 4'-C-methyl nucleoside 5'- monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral inf

Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma

Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. Th

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described: